EGFR and colorectal cancer: However, preclinical models of BRAFV600E colorectal cancer shown that BRAF inhibition causes rapid feedback activation of RAS/MAPK oncogenic signaling pathway through inducing the overexpression of EGFR (43, 44) and required the combination with anti-EGFR monoclonal antibodies to observe antitumoral activity in the clinic (21).